

1 **Mutations that confer resistance to broadly-neutralizing antibodies define**  
2 **HIV-1 variants of transmitting mothers from that of non-transmitting**  
3 **mothers**

4

5 Amit Kumar<sup>1</sup>, Elena E. Giorgi<sup>2</sup>, Joshua J. Tu<sup>1</sup>, David R. Martinez<sup>1#a</sup>, Joshua Eudailey<sup>1</sup>, Michael  
6 Mengual<sup>3#b</sup>, Manukumar Honnayakanahalli Marichannegowda<sup>3#c</sup>, Russell Van Dyke<sup>4</sup>, Feng  
7 Gao<sup>3#d</sup> and Sallie R. Permar<sup>1,5,□</sup>

8

9 <sup>1</sup>Duke Human Vaccine Institute, Duke University Medical Centre, Durham, NC, USA

10 <sup>2</sup>Los Alamos National Laboratory, Los Alamos, NM, USA

11 <sup>3</sup>Department of Medicine, Duke University Medical Centre, Durham, NC, USA

12 <sup>4</sup>Tulane University School of Medicine, New Orleans, LA, USA

13 <sup>5</sup>Department of Pediatrics, Weill Cornell Medicine, New York, NY, USA

14 #aDepartment of Epidemiology, The University of North Carolina at Chapel Hill, Chapel Hill,  
15 NC, USA

16 #bDepartment of Epidemiology, UCLA Fielding School of Public Health, Los Angeles, CA,  
17 USA

18 #cInstitute of Human Virology, University of Maryland School of Medicine, Baltimore, MD,  
19 USA

20 #dNational Engineering Laboratory for AIDS Vaccine, College of Life Science, Jilin  
21 University, Changchun, Jilin, China

22

23

24

25 **Running Title:** MTCT of HIV-1

26

27 \*Corresponding author: Sallie R. Permar

28 Email: [sallie.permar@med.cornell.edu](mailto:sallie.permar@med.cornell.edu)

## 29 **Abstract**

30 Despite considerable reduction of mother-to-child transmission (MTCT) of HIV through use of  
31 maternal and infant antiretroviral therapy (ART), over 150,000 infants continue to become  
32 infected with HIV annually, falling far short of the World Health Organization goal of reaching  
33 <20,000 annual pediatric HIV cases worldwide by 2020. Prior to the widespread use of ART in  
34 the setting of pregnancy, over half of infants born to HIV-infected mothers were protected  
35 against HIV acquisition. Yet, the role of maternal immune factors in this protection against  
36 vertical transmission is still unclear, hampering the development of synergistic strategies to  
37 further reduce MTCT. It has been established that infant transmitted/founder (T/F) viruses are  
38 often resistant to maternal plasma, yet it is unknown if the neutralization resistance profile of  
39 circulating viruses predicts the maternal risk of transmission to her infant. In this study, we  
40 amplified HIV-1 envelope genes (*env*) by single genome amplification and produced  
41 representative Env variants from plasma of 19 non-transmitting mothers from the U.S. Women  
42 Infant Transmission Study (WITS), enrolled in the pre-ART era. Maternal HIV Env variants  
43 from non-transmitting mothers had similar sensitivity to autologous plasma as observed for  
44 non-transmitting variants from transmitting mothers. In contrast, infant variants were on  
45 average 30% less sensitive to paired plasma neutralization compared to non-transmitted  
46 maternal variants from both transmitting and non-transmitting mothers ( $p=0.015$ ). Importantly,  
47 a signature sequence analysis revealed that motifs enriched in *env* sequences from transmitting  
48 mothers were associated with broadly neutralizing antibody (bnAb) resistance. Altogether, our  
49 findings suggest that circulating maternal virus resistance to bnAb-mediated neutralization, but  
50 not autologous plasma neutralization, near the time of delivery, predicts increased MTCT risk.  
51 These results caution that enhancement of maternal plasma neutralization through passive or  
52 active vaccination during pregnancy could drive the evolution of variants fit for vertical  
53 transmission.

## 54 **Author Summary**

55 Despite widespread, effective use of ART among HIV infected pregnant women, new pediatric  
56 HIV infections increase by about 150,000 every year. Thus, alternative strategies will be  
57 required to reduce MTCT and eliminate pediatric HIV infections. Interestingly, in the absence  
58 of ART, less than half of HIV-infected pregnant women will transmit HIV, suggesting natural  
59 immune protection of infants from virus acquisition. To understand the impact of maternal  
60 plasma autologous virus neutralization responses on MTCT, we compared the plasma and bnAb  
61 neutralization sensitivity of the circulating viral population present at the time of delivery in  
62 untreated, HIV-infected transmitting and non-transmitting mothers. While there was no  
63 significant difference in the ability of transmitting and non-transmitting women to neutralize  
64 their own circulating virus strains, specific genetic motifs enriched in variants from transmitting  
65 mothers were associated with resistance to bnAbs, suggesting that acquired bnAb resistance is a  
66 common feature of vertically-transmitted variants. This work suggests that enhancement of  
67 plasma neutralization responses in HIV-infected mothers through passive or active vaccination  
68 could further drive selection of variants that could be vertically transmitted, and cautions the use  
69 of passive bnAbs for HIV-1 prophylaxis or therapy during pregnancy.

## 70 **Introduction**

71 Mother-to-child transmission (MTCT) of HIV-1 was responsible for approximately  
72 160,000 new pediatric infections worldwide in 2018 [1], despite wide availability of maternal  
73 antiretroviral therapy (ART), which can significantly reduce vertical transmission rates [2].  
74 MTCT occurs via three distinct routes: in utero, peripartum, and postpartum through  
75 breastfeeding. Among pregnant women living with HIV-1 not receiving ART, the overall rate  
76 of MTCT of HIV-1 is between 30-40% [3]. However, when ART is used during pregnancy, the  
77 rate of HIV-1 MTCT can be as low as <2% [4]. Despite the success of ART, factors like limited  
78 access and adherence to ART, fetal toxicities [5, 6], development of drug resistant viruses, and  
79 acute maternal infection during pregnancy remain to be addressed to further reduce or eliminate  
80 pediatric HIV-1 infections [7]. Hence, it is clear that additional strategies will be required to  
81 work synergistically with ART to eliminate MTCT of HIV-1.

82 Interestingly, in the absence of maternal or infant ART, the majority of infants exposed  
83 to HIV-1 do not become infected, suggesting a role for natural immunity in protection against  
84 MTCT. Yet, the role of maternal immune response in limiting HIV-1 transmission to the infant  
85 is still ill-defined. Maternal neutralizing antibodies (nAbs) that are transferred through the  
86 placenta to the infant circulation may contribute to this protection. Some studies have suggested  
87 that non-transmitting women have higher magnitude of potentially-protective Env-specific IgG  
88 responses compared to transmitting mothers [8-10]. Yet, other studies have reported higher  
89 levels and breadth of nAbs in women transmitting HIV-1 compared to non-transmitting women  
90 [11-14]. These discordant results could be due to small sample sizes, disparate timing of  
91 maternal and infant sample collection and route of transmission, and failure to assess the impact  
92 of maternal virus variants that have evolved to escape antibody recognition. A better  
93 understanding of the role of maternal antibody responses in the context of viral evolution to

94 escape protective antibodies is therefore needed to inform passive or active vaccine strategies  
95 that can synergize with ART to eliminate MTCT.

96 As maternal IgG is transported through the placenta by an active process mediated by  
97 placental Fc receptor interactions [15], MTCT constitutes an attractive model for vaccine  
98 immunity to understand the role of pre-existing HIV Env-specific IgG in preventing HIV-1  
99 transmission. A previous study from our group demonstrated that infant transmitted/founder  
100 (T/F) viruses were significantly more neutralization resistant to paired maternal plasma when  
101 compared to non-transmitted maternal plasma viruses [16], confirming the pattern suggested by  
102 reports of infant transmitted viruses that are resistant to neutralization by maternal antibodies  
103 [17]. To identify correlates of protection in the context of MTCT, several other studies have  
104 compared the breadth and levels of nAb in sera of transmitting and non-transmitting mothers  
105 using panels of heterologous primary viral isolates of different clades [18-21]. Surprisingly, one  
106 recent study identified increased breadth of plasma nAb responses in transmitting versus non-  
107 transmitting women, indicating that the breadth of maternal neutralizing responses negatively  
108 contributes to MTCT risk [22]. Moreover, we recently described that infant infection can be  
109 initiated by an escape variant of broadly neutralizing antibody (bnAb) present in maternal  
110 plasma, a finding that raises a potential safety concern for the use of passive bnAbs in  
111 pregnancy [23]. However, few studies have been designed to understand the interplay between  
112 the maternal antibodies that are transferred to the infant and neutralization sensitivity of the co-  
113 circulating viruses on vertical virus transmission, leaving a gap in our understanding of what  
114 immune responses should be targeted for maternal immune-based strategies to further reduce  
115 MTCT.

116 To determine whether the profile of autologous plasma and bnAb neutralization  
117 sensitivity of circulating viral populations predicts a mother's risk of vertical virus transmission,  
118 we investigated the autologous plasma and bnAb neutralization sensitivity of the circulating

119 viral population from 35 HIV-1 infected women (16 transmitting and 19 non-transmitting)  
120 present at or near the time of delivery. Circulating envelope (Env) variants were produced from  
121 each mother-infant pair and tested for autologous maternal plasma and bnAb sensitivity.  
122 Additionally, we compared the paired maternal plasma sensitivity of non-transmitted HIV Env  
123 variants from transmitting and non-transmitting mothers to understand the combined effects of  
124 maternal plasma neutralization potency and neutralization sensitivity of circulating viruses on  
125 MTCT risk. This detailed understanding of the role of natural antibody responses and potential  
126 bnAb therapeutics in pregnant women, and how they could impact viruses transmitted to the  
127 infant, is needed to inform the design of immune-based strategies to synergize with ART and to  
128 further reduce and eliminate MTCT.

129

## 130 **Results**

### 131 **HIV-infected transmitting and non-transmitting mother-infant cohort**

132 The U.S.-based Women and Infant Transmission Study (WITS) cohort was utilized in this study  
133 to investigate the combined role of maternal antibodies and virus antibody sensitivity on  
134 vertical virus transmission. The WITS cohort was enrolled in the early 1990's, prior to the  
135 availability of ART prophylaxis, thereby eliminating the strong impact of ART on MTCT risk  
136 and outcome. Two hundred forty-eight study enrollees (83 transmitting and 165 non-  
137 transmitting) from the WITS cohort were screened for study inclusion criteria. Selected  
138 transmitting mothers met the inclusion criteria of peripartum transmission, defined as follows:  
139 infants tested negative for HIV-1 infection at birth by HIV-1 DNA PCR, yet had HIV-1  
140 detectable DNA at one week of age or older [16]. In addition, these HIV-exposed infants were  
141 not breastfed [24]. Each peripartum-transmitting mother was then matched with a non-  
142 transmitting woman via propensity score matching [25] based on maternal plasma viral load,  
143 peripheral CD4<sup>+</sup> T cell count at the time point closest to delivery, mode of delivery, and infant

144 gestational age. We selected a total of 35 HIV-1 infected mothers (19 non-transmitting mothers  
145 and 16 mother-infant transmitting pairs) with adequate plasma volume available for this study.  
146 Ranges for non-transmitting women were 16,360 to 134,325 copies/ml, and 50 to 1045  
147 cell/mm<sup>3</sup> for viral load and CD4<sup>+</sup> T cell counts respectively (Table S1). Maternal plasma viral  
148 load of the selected transmitting mothers ranged from 4,104 to 368,471 copies/ml, and  
149 peripheral blood CD4<sup>+</sup> T cell counts ranged from 107 to 760 cells/mm<sup>3</sup> (Table S2).

150

### 151 **Characterization of complete envelope (*env*) gene sequences from** 152 **transmitting mother-infant pairs and non-transmitting mothers**

153 Single genome amplicons (SGA) for the HIV-1 *env* gene were obtained from the plasma of  
154 transmitting mother-infant pairs as described previously [16]. A total of 463 and 465 *env* SGAs  
155 were obtained from the mother and infant transmitting pairs, respectively. Additionally, plasma  
156 from 19 non-transmitting mothers was used to obtain 645 *env* sequences (Table 1).

**Table 1: Comparison of samples from Non-transmitting and transmitting mothers.**

	<b>Transmitting Mothers</b>	<b>Non-transmitting mothers</b>
# of Samples	16	19
# of SGAs	463	645
Viral Load (copies/ml)	87,193 (4104-368471)	35,784 (16360-134725)
CD4+ T cell count (cells/mm <sup>3</sup> )	413 (107-1049)	506 (50-1045)

157

158 Neighbor-joining phylogenetic trees were created for the *env* genes to understand the diversity  
159 of the viral population present in transmitting mother-infant pairs and non-transmitting mothers  
160 at/near time of delivery. A typical highly diverse chronic HIV-1 population was observed in  
161 each maternal sample (Fig 1&2), while paired/corresponding infant viral populations were on  
162 average less diverse due to recent infection, allowing us to identify 1 or 2 transmitted/founder

163 viruses (T/Fs) at most in each infant (Fig 2). To assess the autologous plasma neutralization  
164 sensitivity of the representative *env* variant population circulating in each transmitting and non-  
165 transmitting mother, we selected a total of 134 and 146 representative *env* variants, respectively,  
166 for Env pseudovirus preparation (5-12 per mother) using an algorithm as described previously  
167 [16] (Figs. 1 & 2).

168

169 **Neutralization sensitivity of circulating HIV-1 Env variants to autologous**  
170 **maternal plasma from peripartum-transmitting and non-transmitting**  
171 **women**

172 HIV Env pseudoviruses were prepared for 280 non-transmitted maternal variants from  
173 transmitting (134 viruses) and non-transmitting mothers (146 viruses), along with 19 infant  
174 T/Fs to assess their Env neutralization sensitivity to autologous maternal plasma. Variable  
175 levels of autologous plasma neutralization sensitivity were observed among non-transmitted *env*  
176 variants. In order to test whether the autologous plasma neutralization sensitivity of circulating  
177 viruses was significantly different between transmitting and non-transmitting mothers, we fitted  
178 a random effect generalized linear model (GLM) with maternal plasma as dependent variable,  
179 transmitting status as fixed effect, and maternal ID as random effect. Using the GLM fit, when a  
180 predictor was found to be significant ( $p < 0.05$ ) via ANOVA test between nested models, we  
181 proceeded to test the magnitude of the effect using a  $\chi^2$  test. In addition, differences in number  
182 of neutralized viruses were tested using a 2-sided Wilcoxon test. We found no significant  
183 difference between transmitting and non-transmitting mothers in the frequency of autologous  
184 plasma neutralization-sensitive viruses ( $p=0.69$  by Wilcoxon test) or the autologous plasma  
185 neutralization titers against circulating Env variants ( $p=0.64$  by ANOVA test). However,  
186 autologous virus neutralization titers against all non-transmitted variants from both non-  
187 transmitting and transmitting mothers were on average 1.5-fold higher than infant T/F viruses

188 from transmitting mothers ( $p=0.005$ ). Furthermore, non-transmitted maternal pseudoviruses  
189 were on average 30% more sensitive to maternal autologous plasma than infant T/Fs and their  
190 closest viruses in the transmitting mothers ( $p=0.015$ ) (Fig.3).

191

## 192 **Env variant amino acid signatures associated with maternal transmission** 193 **phenotype and neutralization susceptibility**

194 While we found no differences in magnitude or breadth of plasma autologous virus  
195 neutralization responses between transmitting and non-transmitting mothers, we sought to  
196 determine if differences in the neutralization sensitivity existed at the viral Env epitope level.  
197 Specifically, we looked for particular motifs in Env variants from both transmitting and non-  
198 transmitting mothers and infants associated with sensitivity to either autologous plasma, and/or  
199 the four second generation HIV-1 bnAbs tested in this study. After excluding infant T/F viruses,  
200 we also looked for specific amino acid residues and/or bnAb sensitivity enriched in either  
201 transmitting mothers or non-transmitting mothers, and therefore correlated with maternal  
202 transmission status. Env pseudoviruses produced from all non-transmitted maternal Env  
203 variants (from both transmitting and non-transmitting mothers) and infant T/F were tested  
204 against a panel of bnAbs that included PG9 (V2 glycan-specific), VRC01 (CD4bs specific),  
205 DH429 (V3 glycan specific) and DH512 (MPER specific) [26-28]. Except for a few exceptions,  
206 all tested maternal Env pseudovirus variants were sensitive to neutralization by these four  
207 bnAbs (Fig.4).

208 Using the LANL tool GenSig  
209 (<https://www.hiv.lanl.gov/content/sequence/GENETICSIGNATURES/gs.html>), we performed  
210 a phylogenetically corrected signature analysis to identify maternal Env sequences motifs that  
211 predicted bnAb sensitivity. The strongest maternal Env amino acid residue associations with  
212 bnAb sensitivity were found with sensitivity to PG9 and VRC01. At HXB2 position 234, amino

213 acid N was found to be associated with resistance to VRC01, whereas D was associated with  
214 sensitivity ( $p=1.5 \times 10^{-05}$  and  $1.54 \times 10^{-05}$  respectively, FDR  $q=0.00016$  and  $7.9 \times 10^{-05}$  respectively;  
215 Table 2). Glycosylation site N234 has been implicated as a contact and resistance site in  
216 previous studies with CD4bs-specific antibodies [29-32] and with VRC01 in particular,  
217 concordant with our findings. In addition, we found site N234 to be strongly associated with  
218 maternal transmission status ( $p=0.0026$ , FDR =0.02; Table 2), with this PNGS enriched in Env  
219 variants from transmitting mothers and the non-PNGS amino acid D enriched in non-  
220 transmitting mothers (Fig. 5).

221 Overall, we found 5 Env residues associated with neutralization sensitivity to VRC01, 4  
222 with PG9, and 2 with DH429 at the FDR <0.05 significance level, while no amino acid position  
223 was found to be associated with DH429 sensitivity (Table 2, Fig. 5). Eight out of the 11 total  
224 sites found in our signature sequence analysis confirmed associations with bnAb sensitivity  
225 previously reported by Bricault et al. [31] (Table 2). Unique to our analysis were the findings  
226 that amino acids I and V at positions 792 and 829, in the cytoplasmic tail of the Env variants,  
227 were associated with resistance to VRC01 and DH429 respectively (Table 2), indicating a  
228 conformational change mediated by these mutations that impede CD4bs bnAb recognition.  
229 Also, never reported before in the literature was Env site K6, where our analysis showed that  
230 mutations away from amino acid N increased resistance to PG9.

231 All together, our signature sequence analysis found five residues associations with  
232 maternal transmission status at FDR <0.05 significance level, of which 3 were also strongly  
233 associated with resistance to at least one tested bnAbs (sites N234, S347, and V833, see Table  
234 S3) and the remaining two, sites A612 and S640, have been identified by Bricault *et. al* [31] to  
235 be associated with increased resistance with V3 glycan-specific bnAbs. Two additional sites,  
236 N386 in V4 and S440, both associated with resistance to V3-specific bnAbs [31], were also

237 found to be associated with maternal transmission status, although at a more marginal  
238 significance level (FDR =0.08 and 0.07 respectively, Table S3).

239 As noted above, the amino acid N at site 234 was found to be associated with resistance  
240 to VRC01 and, at the same time, a PNG at this site was found to be enriched in Env variants  
241 from transmitting mothers. Similarly, at site V833, mutations away from amino acid L were  
242 associated with resistance to both PG9 and VRC01 while at the same time being enriched in  
243 Env variants from transmitting mothers (Fig 5). Taken together, these findings suggest that  
244 acquired resistance to bnAbs may be a factor in selecting for variants that are also fit for vertical  
245 transmission, and this bnAb resistance phenotype may be a more important risk factor for  
246 transmission than resistance to autologous plasma neutralization.

247

## 248 **Role of HIV-1 Env potential N linked Glycosylation sites (PNGS) in bnAb** 249 **sensitivity and maternal transmission status**

250 Previous studies have found a higher number of PNGS in V1 to be associated with  
251 increased resistance to V3-directed antibodies [31]. While differences in the number of PNGS  
252 in the variable regions of Envs from transmitting mothers compared to those from non-  
253 transmitting mothers were not large enough to achieve statistical significance in our cohort, a  
254 signature sequence analysis identified strong correlations between the loss or acquisition of  
255 PNGS in V4 with transmission status (Table 2). Hypervariable regions are extremely hard to  
256 align, especially when combining sequences across different donors, which can potentially

**Table 2: Signature sequence analysis of HIV-1 Env sequence relationship to maternal transmission status, and bnAb sensitivity.**

HXB2 AA Position	Region	Test AA	Association	P value <sup>‡</sup>	Q value <sup>‡</sup>
K6		N	Mutations away from <b>N</b> confer resistance to PG9	0.002	0.023
		E	Mutations away from <b>E</b> confer resistance to PG9.	0.0031	0.03
V87**		K	Mutations to <b>K</b> confer resistance to PG9.	0.001	0.02
		K	Mutations to <b>K</b> confer resistance to VRC01*.	0.013	0.14
		PNG	Loss of a PNG confers resistance to PG9.	0.00012	0.0009
N160**	V2	N	Mutations away from <b>N</b> confer resistance to PG9.	0.00012	0.0015
		K	Mutations to <b>K</b> confer resistance to PG9.	0.00055	0.01
		K	Mutations to <b>K</b> confer resistance to VRC01	0.003	0.045
N229**		N	Mutations away from <b>N</b> confer resistance to VRC01*	0.0035	0.11
		N	Mutations away from N are associated with maternal non-transmitting status.	0.0026	0.02
		D	Mutations to D are associated with maternal non-transmitting status.	0.0033	0.022
N234**		N	Mutations away from <b>N</b> are associated with sensitivity to VRC01.	1.05E-05	0.00016
		D	Mutations to <b>D</b> are associated with sensitivity to VRC01.	1.54E-05	7.90E-05
N295**	V3	N	Mutations away from <b>N</b> are associated with sensitivity to VRC01	0.00085	0.02
		K	Mutations away from K are associated with maternal transmitting status.	0.0014	0.011
S347**		T	Mutations to <b>T</b> confer sensitivity to DH429*	0.0043	0.07
		E	Mutations away from <b>E</b> confer resistance to DH512*	0.01	0.18
		R	Mutations away from <b>R</b> confer resistance to PG9.	9.50E-05	0.0015
R350**		K	Mutations to <b>K</b> confer resistance to PG9.*	0.0038	0.06
A612**		A	Mutations away from A are associated with maternal non-transmitting status.	0.0014	0.011
A640**		S	Mutations to S are associated with maternal non-transmitting status.	0.002	0.015
A792	LLP-3	I	Mutations to <b>I</b> confer resistance to VRC01.	0.00101	0.02
		V	Mutations away from <b>V</b> confer resistance to VRC01.*	0.00109	0.056
		V	Mutations to <b>V</b> confer resistance to DH429.	0.0004	0.0078
V829	LLP-1	V	Mutations to <b>V</b> confer sensitivity to autologous maternal plasma.*	0.0049	0.18
		I	Mutations away from <b>I</b> confer resistance to DH429.	0.00075	0.035
		L	Mutations away from L are associated with maternal transmission status.	0.0012	0.011
		L	Mutations away from <b>L</b> confer resistance to VRC01*	0.012	0.199
V833**		L	Mutations away from <b>L</b> confer resistance to PG9	0.002	0.023
		L	Mutations away from <b>L</b> confer sensitivity to DH429	0.0009	0.031
		V	Mutations to <b>V</b> confer resistance to VRC01.	0.0011	0.02

\* Marginal association ( $0.05 < q < 0.2$ ). \*\* bnAb signature site found in published literature.

<sup>‡</sup> P-value from phylogenetically-corrected Fisher exact test.

<sup>‡</sup> Q-value from FDR multiple testing correction

257 affect the validity of the results. However, three of the signature sites identified in our analysis  
258 as potentially distinct between transmitting and non-transmitting women, N386, N392 and  
259 T394, were at the beginning of V4, proximal to the hypervariable portion of the loop (HXB2  
260 positions 396-410), where it is still possible to align sequences across donors (Table 2).  
261 The strongest Env PNGs site association with transmission status was at T394, where the  
262 acquisition of a PNG was associated with maternal non-transmission status ( $p=0.0009$ , FDR  
263  $=0.0031$ ). At N386, the loss of a PNGS was also associated with maternal non-transmission  
264 status ( $p=0.02$ , FDR  $=0.08$ ), whereas the loss of a PNGS at N392 was associated with increased  
265 resistance to autologous maternal plasma ( $p=0.015$ , FDR  $=0.06$ ) (Table 2 and S3). This site was  
266 the strongest association with maternal plasma sensitivity found among Env sequences in our  
267 cohort. Numerous studies have tracked changes in the Env glycan shield as a mechanism for the  
268 selection of neutralization escape variants [33, 34] and many glycosylation sites in V4 in  
269 particular have been implicated in changes in neutralization sensitivity to V3 and CDbs- bnAbs  
270 [31, 35]. Additional studies with more maternal *env* sequences would be warranted in order to  
271 establish whether variable loop mutations impacting glycan sites render the maternal viruses  
272 more fit for vertical virus transmission by escaping recognition by antibodies that mediate  
273 neutralization or other non-neutralizing antibody functions previously reported to be associated  
274 with MTCT risk [36-39].

275

## 276 **Broadly neutralizing activity of non-transmitting and transmitting maternal** 277 **plasma**

278 As our signature analysis found several bnAb resistant sites enriched in variants from  
279 transmitting mothers compared to variants from non-transmitting mothers, we wondered  
280 whether we could detect broad neutralizing activity from transmitting maternal plasma. We

281 obtained ID<sub>50</sub> from 15 transmitting and 18 non-transmitting mothers (mother 100888 was  
282 excluded due to high murine leukemia virus (MLV) background neutralization activity >60)  
283 against a global panel of 9 viruses. We found no statistically significant difference in number of  
284 neutralized viruses between the transmitting and non-transmitting mothers (p=0.12 by 2-sided  
285 Wilcoxon test). While more non-transmitting mothers (8 out of 18) showed evidence of broad  
286 neutralization activity (defined as neutralization of at least four viruses after MLV background  
287 subtraction) than transmitting mothers (4 out of 15), this difference was not statistically  
288 significant p=0.47 by Fisher exact test) (Fig. 6).

289 Since four transmitting mothers (100014, 100504, 102149, and 100307) showed bnAb activity  
290 against the panel of global viruses (as defined above), we looked specifically at the infant TFs  
291 from those mother-infant pairs and their respective closest maternal sequences to see whether  
292 they were enriched for bnAb resistance amino acid at the significant sites found by our  
293 signature analysis. These sequences were enriched for bnAb resistant amino acids at 5 out of 9  
294 sites (data not shown). Of note, all sequences had a PNG at site 234, which, as previously noted,  
295 is associated with resistance to VRC01. In addition, compared to the closest maternal  
296 sequences, the infant TFs were enriched to the resistant-inducing AA V at both positions 829  
297 and 833.

298

## 299 **Discussion**

300 Maternal and infant ARV treatment has significantly reduced the rate of MTCT to low  
301 levels, but a maternal or infant vaccine is still needed to eliminate pediatric HIV-1. It has been  
302 shown in non-human primate models of sexual transmission that passive immunization of  
303 human monoclonal bnAbs that potently neutralize the challenge virus can protect against virus  
304 acquisition [40-42]. Considering the established protective role of nAbs and limited success of  
305 HIV vaccines that do not elicit bnAbs, it is likely that a vaccine would have to induce bnAbs in

306 order to be highly effective against HIV-1 acquisition [43-46]. MTCT of HIV-1 is a unique  
307 setting where the infant receives maternal antibodies generated against autologous viruses to  
308 which the infant is exposed from the mother *in utero* [47]. As over half of infants are naturally  
309 protected against MTCT, it is believed that protective immune factors, such as maternal  
310 antibodies, may prevent the transmission of viruses. Yet, extensive studies of this phenomenon  
311 have not firmly established a protective role of maternal antibodies, which may be related to the  
312 need to study the interplay between the maternal antibodies and autologous viruses to which the  
313 infant is exposed. In this study, we compared the autologous neutralizing antibody responses  
314 against the maternal viruses present near the time of delivery in peripartum transmitting and  
315 non-transmitting mothers to determine if the ability of the mother to neutralize her own viruses  
316 predicts her risk of vertical virus transmission. Despite infant transmitted variants consistently  
317 demonstrating autologous plasma neutralization resistance, our analysis revealed no statistically  
318 significant differences in the magnitude or frequency of neutralization responses against  
319 circulating autologous viruses from transmitting and non-transmitting mothers. Thus, the  
320 frequency and potency of maternal neutralization responses against her own circulating viruses  
321 do not appear to establish the risk of vertical virus transmission.

322 We focused on peripartum-transmitting mothers from the WITS cohort who did not  
323 receive ART, thereby eliminating the impact of ART on virus selection [24]. Further, to  
324 eliminate the clinical factors known to be associated with risk of MTCT, propensity score  
325 criteria was used to match non-transmitting mothers with peripartum transmitting mothers  
326 which included the CD4+ T cell count, viral load, and mode of delivery. In total, we obtained  
327 1108 Env variants (463 T and 645 NT) from 16 transmitting and 19 non-transmitting mothers.  
328 With an average of 30 sequences per mother (range 20-42 sequences), we are 95% confident  
329 that these Env variants represented the heterogeneity of each maternal sample present at the  
330 time of delivery at a population frequency of 15% or higher. Not many prior studies of the role

331 of maternal antibodies in MTCT have included autologous maternal virus population sequences  
332 or functional autologous viruses in their investigations. Other studies have used either partial  
333 Env sequences to represent the maternal viral diversity or a small number of transmitting and  
334 non-transmitting mother-infant pairs, which limits power to detect sequence diversity among  
335 each group [48, 49]. Yet, this study is one of the first to generate autologous single genome Env  
336 variants from transmitting and non-transmitting mothers to accurately assess the function of  
337 maternal antibodies against co-circulating vertically transmitted and non-transmitted maternal  
338 variants.

339 To investigate our hypothesis that variants from non-transmitting mothers are more  
340 sensitive to autologous plasma than in transmitting mothers, Env pseudoviruses were prepared  
341 using the SGA *env* sequences from the maternal plasma systematically selected as  
342 representative of maternal viral population in order to cover the diversity of the HIV-1  
343 population in each mother. Interestingly, we did not observe statistically significant differences  
344 in neutralization sensitivity among viruses between transmitting and non-transmitting mothers.  
345 There are only a couple of comparable studies where conflicting results have been observed.  
346 Baan et.al [50] compared autologous plasma neutralization sensitivity of viral variants from 7  
347 transmitting and 4 non-transmitting mothers and found that viruses from transmitting mothers  
348 were more sensitive to maternal plasma neutralization than the variants from non-transmitting  
349 mothers. However, plasma samples used in this study were not contemporaneous, further  
350 complicating the analysis. On the other hand, a study by Milligan *et. al* [51] showed that there is  
351 no difference in neutralization sensitivity of viral variants from transmitting and non-  
352 transmitting mothers as observed in this study. However, the viral variants in Milligan *et.al*  
353 study were obtained using PBMC DNA which may not represent the circulating variants at the  
354 time of transmission. Notably, in the present study, peripartum transmitting and non-  
355 transmitting mothers were carefully clinically matched by a propensity score and the plasma

356 employed to isolate viruses was from the delivery time point. Additionally, utilizing a pre-ART  
357 era cohort, eliminated viral selection pressure due to ART and further strengthening the results.

358         When we compared infant T/Fs and their phylogenetically closely related maternal  
359 variants with non-transmitted variants from both group of mothers, infant T/Fs and their closely  
360 related maternal variants were significantly more resistant to paired maternal plasma. This  
361 finding suggests that neutralization resistance to paired maternal plasma is a defining feature of  
362 infant transmitted variants. While a few studies [17] have indicated that virus(es) transmitted to  
363 infants are neutralization escape variants, other studies contradict these findings [48, 52, 53].  
364 These conflicting results could be due to difference in timing of maternal-infant sample  
365 collection, small sample sizes, and undefined routes of transmission. Importantly, we used well-  
366 defined criteria for peripartum transmission with a large sample size, adding to the robustness  
367 of results. Additionally, isolation of 20-30 SGAs per infant and maternal plasma sample and  
368 neutralization testing of 5-12 viruses per mother provide considerably more functional viral  
369 sequence data than many previous studies.

370         Glycosylation sites are known to be targets of numerous bnAbs and hence may have a  
371 role in driving the selection of neutralization escape variants in infant infection [33]. However,  
372 we did not see any significant differences in number of PNGS and variable loop lengths among  
373 infant T/F and non-transmitted maternal variants. In contrast, a few studies have investigated  
374 the number of PNGS and variable loop length of infant T/Fs and non-transmitted maternal  
375 variants from transmitting mother-infant pairs and found that transmitting viruses had shorter  
376 variable loop lengths and less PNGS [48, 49]. Several studies involving chronic HIV  
377 transmission in adults where escape variants have been reported to have longer variable loop  
378 lengths and more PNGS, indicating that virus escape from maternal antibodies in MTCT may  
379 be distinct from that of chronic infection [54-56].

380 Previously, we found that maternal V3-specific IgG levels and weak (tier 1)  
381 neutralization response predicted a reduced risk of transmission in this cohort [21]. In a follow-  
382 up study, we showed that infant T/Fs are escape variants of V3 region-specific antibodies [23].  
383 Moreover, it has been shown in rhesus macaque studies that passive immunization by  
384 polyclonal or weakly-neutralizing nAbs can reduce vertical transmission risk [57, 58]. So far,  
385 there have been two studies in humans involving maternal passive immunizations by polyclonal  
386 HIVIG to prevent MTCT and both did not show any additional benefit to ART [59, 60]. These  
387 results indicate that targeting specific epitopes of autologous viruses may be required for a  
388 successful vaccine to prevent MTCT. Several second generation bnAbs have been isolated from  
389 chronic HIV-1 infected patients in recent years and are under study as a passive immunization  
390 and/or therapy [61-64]. Hence, it is important to investigate the neutralization efficacy of  
391 prototype bnAbs i.e. VRC01 (CD4bs specific), PG9 (V1V2 glycan specific), DH512 (MPER  
392 specific) and DH429 (V3 glycan specific) against all Env variants from transmitting and non-  
393 transmitting mothers and infant T/Fs to determine what the clinical impact of bnAb prophylaxis  
394 and/or therapeutics may be in this setting. Almost all the Env variants tested were sensitive to  
395 these bnAbs except few maternal variants. This finding supports the potential efficacy of the  
396 ongoing clinical assessment of VRC01 bnAb passive immunization of high risk, HIV-exposed  
397 infants as a strategy to further reduce infant HIV acquisition [65]. Also, a comprehensive recent  
398 study by Bricault et al. [31] showed the advantages of epitope-based vaccine design based on  
399 signature sequence analysis of bnAb-resistant and sensitive variants. Using neutralization  
400 epitopes for the bnAbs used in this study were previously defined, a signature sequence analysis  
401 was performed to identify amino acids associated with transmission and resistance. We found a  
402 number of genetic motifs that were significantly enriched in Env variants from transmitting  
403 mothers at positions that were also associated with resistance to V2-, CD4bs-, and MPER-  
404 specific bnAbs like PG9, VRC01, and DH512. Interestingly, 3 out of 5 motifs identified in our

405 signature analysis to be significantly associated with maternal transmission status at the FDR  
406  $<0.05$  level, were also associated with increased resistance to either VRC01 or PG9 (Table 2).  
407 Importantly, a signature sequence analysis of viral variants from transmitting and non-  
408 transmitting mothers demonstrated that certain V1 and V4 loop region amino acids associated  
409 with maternal transmission potential, but not necessarily neutralizing sensitivity, which may  
410 suggest escape from other maternal antibody functions, such as ADCC, can define the  
411 transmission potential of HIV Env variants. Many amino acid positions from region C1, V1V2,  
412 C4 and cytoplasmic tail were also associated with viral resistance to the autologous plasma, yet  
413 not viral transmission potential. Further, we found 2 glycosylation sites in V4 that associated  
414 with neutralization sensitivity, one associated with maternal transmission status and one with  
415 resistance to autologous maternal plasma. Interestingly, at the FDR  $<0.1$  significance level, we  
416 found 7 signature sites associated with maternal transmission status, of which 3 were also  
417 associated with neutralizations sensitivity to PG9, VRC01, and/or DH429, and the remaining  
418 four were all sites previously found to be associated with neutralization sensitivity to V3-  
419 specific bnAbs [31], suggesting that bnAb-mediated immune pressure may be a major force  
420 driving selection of resistant variants in transmitting mothers that are also fit for MTCT  
421 transmission.

422         Since some studies have shown association of nAbs presence or titers against  
423 heterologous HIV-1 strains as risk factor for MTCT [11, 12], we also investigated the bnAb  
424 activity of the plasma from transmitting and non-transmitting mothers against a reference panel  
425 of 9 diverse global HIV-1 viruses. While we did see a trend towards more transmitting than  
426 non-transmitting women with pre-defined plasma bnAb activity, defined as neutralization of at  
427 least 4 of 9 tier 2 heterologous viruses on the global panel, we did not observe statistically  
428 significant difference in the breadth of neutralization activity in the plasma of 16 transmitting  
429 and 18 non-transmitting maternal plasma. Our results are in contrast to a study of breast-feeding

430 HIV-1 transmission pairs [22] where transmitting mother showed higher breadth of  
431 heterologous virus neutralizing activity compared to non-transmitting mothers. However,  
432 different mode of transmission could have led to this difference in results. Also, we did observe  
433 higher MLV neutralizing activity among the non-transmitting mothers in this study, potentially  
434 indicating distinct sample handling or exposure to ART. Previously, we had shown that infant  
435 T/Fs are the escape variants of maternal plasma [16]. Our results along with previous studies  
436 indicate that passive or active vaccines inducing bnAb response in pregnant women will need to  
437 be used with caution to prevent MTCT.

438 Overall, this is the largest study comparing plasma neutralization responses against  
439 autologous viruses in HIV-infected transmitting and non-transmitting mothers. This unique  
440 study design revealed that while infant T/Fs are more likely to be escape variants from maternal  
441 neutralization responses when compared with the non-transmitted maternal variants, the  
442 mother's natural ability to neutralize her own circulating viruses does not define a mother's  
443 MTCT risk. Concerningly, we identified that maternal transmission status was tied to Env  
444 amino acid signatures that confer resistance to bnAbs, including those being used in clinical  
445 trials for HIV-1 prevention and therapy [66, 67]  
446 (<https://clinicaltrials.gov/ct2/show/NCT03571204>). These results caution the use of passive or  
447 active vaccine strategies targeting plasma bnAb activity in pregnant women and indicate that  
448 more work will need to address the risks of bnAb escape variants that are fit for virus  
449 transmission. Moreover, they suggest that there are functional antibody responses other than  
450 nAbs, such as ADCC, that may be more important protective factors that define transmitting  
451 mothers from non-transmitting mothers. Thus, maternal vaccine strategies to further reduce  
452 pediatric HIV infections should be designed to induce multispecific neutralization responses  
453 and potentially other non-neutralizing antibody functions that provide potent protection when

454 transferred to the infant, but also eliminate the risk of selecting viruses that can escape maternal  
455 antibody functions and become vertically-transmitted variants.

456

## 457 **Acknowledgements**

458 We acknowledge Youyi Fong in selecting samples from the WITS cohort, Bette Korber and  
459 Kshitij Wagh for useful discussions on the signature analysis. We would also like to  
460 acknowledge the support of Pediatric HIV/AIDS Cohort Study (PHACS) team for their  
461 management of the Women and Infant Transmission Study cohort repository samples,  
462 supported by the *Eunice Kennedy Shriver* National Institute of Child Health and Human  
463 Development (HD052102 and HD052104). This work was financially supported by National  
464 Institute of Health (NIH) with the RO1 grant number AI122909.

465

## 466 **Materials and Methods**

### 467 **Study subjects and sample collection**

468 A total of 35 HIV-1 infected women living with HIV-1 (16 transmitting and 19 non-  
469 transmitting mothers) were selected from the WITS (Women Infant Transmission Study) cohort  
470 based on propensity score and adequate plasma volume (2.0 ml). The WITS cohort was enrolled  
471 in the pre-ART era during 1993/1994 in US, consisting of HIV-1 subtype B infections.  
472 Propensity score based on established risk factors for MTCT, including maternal CD4<sup>+</sup> count,  
473 plasma viral load, and mode of delivery was used to match non-transmitting women to  
474 peripartum-transmitting women [68].

### 475 **Ethics statement**

476 Samples used in this study were obtained with informed consent from participants of the  
477 Women Infant Transmission Study (WITS) [24]. WITS repository cohort samples were  
478 received as de-identified material and were deemed as research not involving human subjects  
479 by Duke University Institutional Review Board (IRB). The reference number for that protocol  
480 and determination is Pro00016627.

### 481 **Viral RNA extraction and SGA analysis**

482 Viral RNA extractions and SGA analyses were done as described previously [16]. Briefly, viral  
483 RNA was purified from the plasma sample from each patient by the Qiagen QiaAmp viral RNA  
484 mini kit and subjected to cDNA synthesis using 1X reaction buffer, 0.5 mM of each  
485 deoxynucleoside triphosphate (dNTP), 5 mM DTT, 2 U/mL RNaseOUT, 10 U/mL of  
486 SuperScript III reverse transcription mix (Invitrogen), and 0.25 mM antisense primer 1.R3.B3R  
487 (5'-ACTACTTGAAGCACTCAAGGCAAGCT TTATTG-3'). The resulting cDNA was PCR  
488 amplified using Platinum Taq DNA polymerase High Fidelity (Invitrogen) so that < 30% of  
489 reactions were positive in order to maximize the likelihood of amplification from a single

490 genome. A second round of PCR amplification was conducted using 2µl of the first round  
491 products as template. Round 1 amplification conditions were 1 cycle of 94°C for 2 minutes, 35  
492 cycles of 94°C for 15 seconds, 58°C for 30 seconds, and 68°C for 4 minutes, followed by 1  
493 cycle of 68°C for 10 minutes. Round 2 conditions were one cycle of 94°C for 2 minutes, 45  
494 cycles of 94°C for 15 seconds, 58°C for 30 seconds, and 68°C for 4 minutes, followed by 1  
495 cycle of 68°C for 10 minutes. Round 2 PCR amplicons were visualized by agarose gel  
496 electrophoresis and sequenced for envelope gene using an ABI3730xl genetic analyzer (Applied  
497 Biosystems). Partially overlapping sequences from each amplicon were assembled and edited  
498 using Sequencher (Gene Codes, Inc).

#### 499 **Sequence alignment**

500 All maternal and infant envelope sequences were aligned using the Gene Cutter tool available at  
501 the Los Alamos National Laboratory (LANL) website  
502 ([http://www.hiv.lanl.gov/content/sequence/GENE\\_CUTTER/cutter.html](http://www.hiv.lanl.gov/content/sequence/GENE_CUTTER/cutter.html)) and then refined  
503 manually. Full-length envelope sequences were manually edited in Seaview [69].

#### 504 **Pseudovirus preparation**

505 CMV promoter was added to maternal envelope SGAs using the overlapping PCR method  
506 and used to prepare pseudoviruses [70]. Briefly, pseudoviruses were prepared by transfection in  
507 HEK293T (ATCC, Manassas, VA) cells with 4µg of CMV-env PCR product and 4µg of env-  
508 deficient HIV plasmid DNA using the FuGene 6 transfection reagent (Promega) in a T75 flask.  
509 Two days after transfection, the culture supernatant containing pseudoviruses was harvested,  
510 filtered, aliquoted, and stored at -80°C. An aliquot of frozen pseudovirus was used to measure  
511 the infectivity in TZM-bl cells. 20µl of pseudovirus was distributed in duplicate to 96-well flat  
512 bottom plates (Co-star). Then, freshly trypsinized TZM-bl cells were added (10,000 cells/well  
513 in Dulbecco's modified Eagle's medium (DMEM)-10% fetal bovine serum (FBS) containing

514 HEPES and 10 $\mu$ g/ml of DEAE-dextran). After 48 h of incubation at 37°C, 100 $\mu$ l of medium  
515 was removed from the wells. 100 $\mu$ l of luciferase reagent was added to each well and incubated  
516 at room temperature for 2 min. 100 $\mu$ l of the lysate was transferred to a 96-well black solid plate  
517 (Costar), and the luminescence was measured using the Bright-Glo™ luminescence reporter  
518 gene assay system (Promega).

### 519 **Neutralization assays**

520 Neutralizing antibody activity was measured in 96-well culture plates by using Tat-regulated  
521 luciferase (Luc) reporter gene expression to quantify reductions in virus infection in TZM-bl  
522 cells. TZM-bl cells were obtained from the NIH AIDS Research and Reference Reagent  
523 Program, as contributed by John Kappes and Xiaoyun Wu. Assays were performed with HIV-1  
524 Env-pseudotyped viruses as described previously [71, 72]. Viruses (~50,000 relative light unit  
525 equivalents) were pre-incubated with plasma (starting dilution 1:20) or Mab (starting  
526 concentration 25 $\mu$ g/ml) serially diluted 3-fold in a 96 well plate for 1 hr at 37°C before addition  
527 of TZM-bl cells. Following a 48-hr incubation, cells were lysed and Luc activity determined  
528 using a microtiter plate luminometer and Briteglo (Promega). Neutralization titers are the  
529 sample dilution (for serum/plasma) or antibody concentration (monoclonal antibodies) at which  
530 relative luminescence units (RLU) were reduced by 50% compared to RLU in virus control  
531 wells after subtraction of background RLU in cell control wells. Serum/plasma samples were  
532 heat-inactivated at 56°C for 1 hr prior to assay.

### 533 **Statistical analyses**

534 Infant T/Fs were identified for each sample as described previously [16, 73]. Briefly, infant  
535 envelope sequences were aligned using Seaview and consensus sequence was generated. SGA  
536 similar to consensus sequence was used as infant T/F. To select maternal non-transmitted  
537 variants and capture the most divergent sequences from the infant T/F, we devised an algorithm

538 as previously described [16]. The algorithm finds the most variable positions in the amino acid  
539 alignment and ranks all sequences with respect to the frequencies at these positions. Sequences  
540 are then selected starting from the most divergent based on motif coverage as observed in the  
541 alignment and in the phylogenetic tree (in other words, if a group of diverging sequences all  
542 share the same motif, only one in the group and/or tree node is selected). Differences in number  
543 of neutralized viruses were tested using a 2-sided Wilcoxon test. Magnitude of maternal plasma  
544 from transmitting and non-transmitting mothers, and between transmitted and non-transmitted  
545 variants, were compared using a random-effect generalized linear model (GLM) using maternal  
546 plasma as dependent variable, transmitting status as fixed effect, and maternal ID as random  
547 effect. Using the GLM fit, when a predictor was found to be significant via ANOVA test  
548 between nested models, we proceeded to test the magnitude of the effect using a  $\chi^2$  test. All  
549 tests were conducted on the R platform [74] [<http://www.R-project.org>]. The GLM was  
550 implemented using the lme4 package [75].

551 Plasma neutralization titers were treated as positive if above the 1:60 dilution threshold. MLV  
552 background was subtracted when detected, else a nominal threshold of 60 was subtracted  
553 instead. Breadth was measured as number of positive titers after subtracting background as  
554 described, and groups were compared using a 2-sided Wilcoxon test (implemented in R).

### 555 **Genetic signature analysis**

556 We performed phylogenetically corrected signature analyses to identify amino acid and  
557 glycosylation sites associated with transmitting vs. non-transmitting status, maternal plasma,  
558 and sensitivity to bNAbs PG9, DH512, DH429 and VRC01. This was done using the LANL  
559 tool GenSig [<https://www.hiv.lanl.gov/content/sequence/GENETICSIGNATURES/gc.html>],  
560 which identifies sites of interest using a phylogenetically corrected approach to minimize false  
561 positives due to lineage effects [31, 76, 77]. Briefly, at each site, GenSig performs a Fisher

562 exact test of a 2x2 matrix where the rows represent the two states of a feature (i.e. transmitting  
563 vs. non-transmitting, or above or below threshold for neutralization sensitivity data), and the  
564 columns represent the two possible ancestral states in the phylogenetic tree. For example, if A is  
565 the amino acid being tested, then GenSig performs two tests, one where "A" is the ancestral  
566 state, and one where "!A" is the ancestral state. For the former, the columns in the Fisher exact  
567 matrix will be the counts of how many leaves came from an A->!A transition and how many  
568 from A->A respectively, whereas for the latter the counts will be for !A->A and !A->!A  
569 respectively. For more details see the GenSig tool explanation  
570 (<https://www.hiv.lanl.gov/content/sequence/GENETICSIGNATURES/help.html>). Because our  
571 data consists of multiple sequences from each mother-infant pair, ignoring this phylogenetic  
572 correction could potentially yield to spurious associations driven by within-subject correlations.

573 For this analysis, maternal plasma neutralization sensitivity (above or below  
574 neutralization threshold of 1:50) and transmission status were treated as dichotomous variables,  
575 whereas PG9, DH429, DH512 and VRC01 IC50s were considered multiple ways (upper  
576 quartile vs. lower three, lower quartile vs. upper three, and above/below threshold). For  
577 robustness, we deemed as viable results only sites that were confirmed with at least two  
578 approaches across all considered phenotypes or that had previously been found to be associated  
579 with sensitivity in the literature. For multiple testing correction we used a false discovery rate  
580 (FDR) of  $q < 0.2$  [78] to screen the results, and then tiered the strength of the associations by  
581  $q < 0.05$ ,  $q < 0.1$  and  $q < 0.2$  significance levels, the latter being the most marginal findings.  
582 Logo plots were created using the LANL tool AnalyzeAlign  
583 ([https://www.hiv.lanl.gov/content/sequence/ANALYZEALIGN/analyze\\_align.html](https://www.hiv.lanl.gov/content/sequence/ANALYZEALIGN/analyze_align.html)).

#### 584 **bnAb Activity analysis of plasma from transmitting and non-transmitting mothers**

585 Neutralization of 10 viruses incorporating a reference Env from the global panel was tested  
586 against a 1:60 plasma dilution from non-transmitting mothers as described previously [79-81].

587 Pseudovirus prepared with Env glycoprotein from Murine Leukemia Virus (SVA.MLV) was  
588 used as a negative control.  
589

## 590 **References**

- 591 1. Global HIV & AIDS statistics — 2020 fact sheet. 2020.
- 592 2. Fowler MG, Qin M, Fiscus SA, Currier JS, Flynn PM, Chipato T, et al. Benefits and Risks of  
593 Antiretroviral Therapy for Perinatal HIV Prevention. *N Engl J Med.* 2016;375(18):1726-37.
- 594 3. Wolinsky SM, Wike CM, Korber BT, Hutto C, Parks WP, Rosenblum LL, et al. Selective  
595 transmission of human immunodeficiency virus type-1 variants from mothers to infants. *Science.*  
596 1992;255(5048):1134-7.
- 597 4. Mugwaneza P, Lyambabaje A, Umubyeyi A, Humuza J, Tsague L, Mwanyumba F, et al.  
598 Impact of maternal ART on mother-to-child transmission (MTCT) of HIV at six weeks  
599 postpartum in Rwanda. *BMC Public Health.* 2018;18(1):1248.
- 600 5. Chen JY, Ribaud HJ, Souda S, Parekh N, Ogwu A, Lockman S, et al. Highly active  
601 antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. *J*  
602 *Infect Dis.* 2012;206(11):1695-705.
- 603 6. Coelho AV, Tricarico PM, Celsi F, Crovella S. Antiretroviral Treatment in HIV-1-Positive  
604 Mothers: Neurological Implications in Virus-Free Children. *Int J Mol Sci.* 2017;18(2).
- 605 7. Yeganeh N, Kerin T, Ank B, Watts DH, Camarca M, Joao EC, et al. Human  
606 Immunodeficiency Virus Antiretroviral Resistance and Transmission in Mother-Infant Pairs  
607 Enrolled in a Large Perinatal Study. *Clin Infect Dis.* 2018;66(11):1770-7.
- 608 8. Bongertz V, Costa CI, Veloso VG, Grinsztejn B, Filho EC, Calvet G, et al. Neutralization  
609 titres and vertical HIV-1 transmission. *Scand J Immunol.* 2002;56(6):642-4.
- 610 9. Bongertz V, Costa CI, Veloso VG, Grinsztejn B, Joao Filho EC, Calvet G, et al. Vertical  
611 HIV-1 transmission: importance of neutralizing antibody titer and specificity. *Scand J Immunol.*  
612 2001;53(3):302-9.

- 613 10. Scarlatti G, Albert J, Rossi P, Hodara V, Biraghi P, Muggiasca L, et al. Mother-to-child  
614 transmission of human immunodeficiency virus type 1: correlation with neutralizing antibodies  
615 against primary isolates. *J Infect Dis.* 1993;168(1):207-10.
- 616 11. Braibant M, Barin F. The role of neutralizing antibodies in prevention of HIV-1 infection:  
617 what can we learn from the mother-to-child transmission context? *Retrovirology.* 2013;10:103.
- 618 12. Blish CA, Blay WM, Haigwood NL, Overbaugh J. Transmission of HIV-1 in the face of  
619 neutralizing antibodies. *Curr HIV Res.* 2007;5(6):578-87.
- 620 13. Mutucumarana CP, Eudailey J, McGuire EP, Vandergrift N, Tegha G, Chasela C, et al.  
621 Maternal Humoral Immune Correlates of Peripartum Transmission of Clade C HIV-1 in the  
622 Setting of Peripartum Antiretrovirals. *Clin Vaccine Immunol.* 2017;24(8).
- 623 14. Overbaugh J. Mother-infant HIV transmission: do maternal HIV-specific antibodies protect  
624 the infant? *PLoS Pathog.* 2014;10(8):e1004283.
- 625 15. Martinez DR, Fong Y, Li SH, Yang F, Jennewein MF, Weiner JA, et al. Fc Characteristics  
626 Mediate Selective Placental Transfer of IgG in HIV-Infected Women. *Cell.* 2019;178(1):190-  
627 201 e11.
- 628 16. Kumar A, Smith CEP, Giorgi EE, Eudailey J, Martinez DR, Yusim K, et al. Infant  
629 transmitted/founder HIV-1 viruses from peripartum transmission are neutralization resistant to  
630 paired maternal plasma. *PLoS Pathog.* 2018;14(4):e1006944.
- 631 17. Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, et al.  
632 Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from  
633 mother to infant. *J Virol.* 2006;80(2):835-44.
- 634 18. Barin F, Jourdain G, Brunet S, Ngo-Giang-Huong N, Weerawatgoompa S, Karnchanamayul  
635 W, et al. Revisiting the role of neutralizing antibodies in mother-to-child transmission of HIV-1.  
636 *J Infect Dis.* 2006;193(11):1504-11.

- 637 19. Chaillon A, Wack T, Braibant M, Mandelbrot L, Blanche S, Warszawski J, et al. The breadth  
638 and titer of maternal HIV-1-specific heterologous neutralizing antibodies are not associated with  
639 a lower rate of mother-to-child transmission of HIV-1. *J Virol.* 2012;86(19):10540-6.
- 640 20. Samleerat T, Thenin S, Jourdain G, Ngo-Giang-Huong N, Moreau A, Leechanachai P, et al.  
641 Maternal neutralizing antibodies against a CRF01\_AE primary isolate are associated with a low  
642 rate of intrapartum HIV-1 transmission. *Virology.* 2009;387(2):388-94.
- 643 21. Permar SR, Fong Y, Vandergrift N, Fouda GG, Gilbert P, Parks R, et al. Maternal HIV-1  
644 envelope-specific antibody responses and reduced risk of perinatal transmission. *J Clin Invest.*  
645 2015;125(7):2702-6.
- 646 22. Ghulam-Smith M, Olson A, White LF, Chasela CS, Ellington SR, Kourtis AP, et al.  
647 Maternal but Not Infant Anti-HIV-1 Neutralizing Antibody Response Associates with Enhanced  
648 Transmission and Infant Morbidity. *mBio.* 2017;8(5).
- 649 23. Martinez DR, Tu JJ, Kumar A, Mangold JF, Mangan RJ, Goswami R, et al. Maternal  
650 Broadly Neutralizing Antibodies Can Select for Neutralization-Resistant, Infant-  
651 Transmitted/Founder HIV Variants. *mBio.* 2020;11(2).
- 652 24. Rich KC, Fowler MG, Mofenson LM, Abboud R, Pitt J, Diaz C, et al. Maternal and infant  
653 factors predicting disease progression in human immunodeficiency virus type 1-infected infants.  
654 Women and Infants Transmission Study Group. *Pediatrics.* 2000;105(1):e8.
- 655 25. JJ H. Sample selection bias as a specification error. *Econometrica.* 1979;47(1):153-61.
- 656 26. Pegu A, Hessel AJ, Mascola JR, Haigwood NL. Use of broadly neutralizing antibodies for  
657 HIV-1 prevention. *Immunol Rev.* 2017;275(1):296-312.
- 658 27. Cohen YZ, Caskey M. Broadly neutralizing antibodies for treatment and prevention of HIV-  
659 1 infection. *Curr Opin HIV AIDS.* 2018;13(4):366-73.
- 660 28. Barin F, Braibant M. HIV-1 antibodies in prevention of transmission. *Curr Opin HIV AIDS.*  
661 2019;14(4):273-8.

- 662 29. Zhou T, Lynch RM, Chen L, Acharya P, Wu X, Doria-Rose NA, et al. Structural Repertoire  
663 of HIV-1-Neutralizing Antibodies Targeting the CD4 Supersite in 14 Donors. *Cell*.  
664 2015;161(6):1280-92.
- 665 30. Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, et al. Strain-Specific V3 and  
666 CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant  
667 Viruses. *Cell Host Microbe*. 2015;18(3):354-62.
- 668 31. Bricault CA, Yusim K, Seaman MS, Yoon H, Theiler J, Giorgi EE, et al. HIV-1 Neutralizing  
669 Antibody Signatures and Application to Epitope-Targeted Vaccine Design. *Cell Host Microbe*.  
670 2019;26(2):296.
- 671 32. West AP, Jr., Scharf L, Horwitz J, Klein F, Nussenzweig MC, Bjorkman PJ. Computational  
672 analysis of anti-HIV-1 antibody neutralization panel data to identify potential functional epitope  
673 residues. *Proc Natl Acad Sci U S A*. 2013;110(26):10598-603.
- 674 33. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and  
675 escape by HIV-1. *Nature*. 2003;422(6929):307-12.
- 676 34. Wagh K, Kreider EF, Li Y, Barbian HJ, Learn GH, Giorgi E, et al. Completeness of HIV-1  
677 Envelope Glycan Shield at Transmission Determines Neutralization Breadth. *Cell Rep*.  
678 2018;25(4):893-908 e7.
- 679 35. Alam SM, Aussedat B, Vohra Y, Meyerhoff RR, Cale EM, Walkowicz WE, et al. Mimicry  
680 of an HIV broadly neutralizing antibody epitope with a synthetic glycopeptide. *Sci Transl Med*.  
681 2017;9(381).
- 682 36. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. HIV-specific antibodies  
683 capable of ADCC are common in breastmilk and are associated with reduced risk of  
684 transmission in women with high viral loads. *PLoS Pathog*. 2012;8(6):e1002739.

- 685 37. Tranchat C, Van de Perre P, Simonon-Sorel A, Karita E, Benchaib M, Lepage P, et al.  
686 Maternal humoral factors associated with perinatal human immunodeficiency virus type-1  
687 transmission in a cohort from Kigali, Rwanda, 1988-1994. *J Infect.* 1999;39(3):213-20.
- 688 38. Ljunggren K, Moschese V, Broliden PA, Giaquinto C, Quinti I, Fenyo EM, et al. Antibodies  
689 mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children  
690 born to human immunodeficiency virus-infected mothers. *J Infect Dis.* 1990;161(2):198-202.
- 691 39. Broliden K, Sievers E, Tovo PA, Moschese V, Scarlatti G, Broliden PA, et al. Antibody-  
692 dependent cellular cytotoxicity and neutralizing activity in sera of HIV-1-infected mothers and  
693 their children. *Clin Exp Immunol.* 1993;93(1):56-64.
- 694 40. Van Rompay KK, Berardi CJ, Dillard-Telm S, Tarara RP, Canfield DR, Valverde CR, et al.  
695 Passive immunization of newborn rhesus macaques prevents oral simian immunodeficiency  
696 virus infection. *J Infect Dis.* 1998;177(5):1247-59.
- 697 41. Foresman L, Jia F, Li Z, Wang C, Stephens EB, Sahni M, et al. Neutralizing antibodies  
698 administered before, but not after, virulent SHIV prevent infection in macaques. *AIDS Res Hum*  
699 *Retroviruses.* 1998;14(12):1035-43.
- 700 42. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, Hayes D, et al. Protection of  
701 Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer  
702 of neutralizing antibodies. *J Virol.* 1999;73(5):4009-18.
- 703 43. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al.  
704 Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. *N Engl J*  
705 *Med.* 2009;361(23):2209-20.
- 706 44. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al.  
707 Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *N Engl J Med.*  
708 2012;366(14):1275-86.

- 709 45. Burton DR. Advancing an HIV vaccine; advancing vaccinology. *Nat Rev Immunol*.  
710 2019;19(2):77-8.
- 711 46. Cohen KW, Frahm N. Current views on the potential for development of a HIV vaccine.  
712 *Expert Opin Biol Ther*. 2017;17(3):295-303.
- 713 47. Lehman DA, Farquhar C. Biological mechanisms of vertical human immunodeficiency virus  
714 (HIV-1) transmission. *Rev Med Virol*. 2007;17(6):381-403.
- 715 48. Russell ES, Kwiek JJ, Keys J, Barton K, Mwapasa V, Montefiori DC, et al. The genetic  
716 bottleneck in vertical transmission of subtype C HIV-1 is not driven by selection of especially  
717 neutralization-resistant virus from the maternal viral population. *J Virol*. 2011;85(16):8253-62.
- 718 49. Kishko M, Somasundaran M, Brewster F, Sullivan JL, Clapham PR, Luzuriaga K. Genotypic  
719 and functional properties of early infant HIV-1 envelopes. *Retrovirology*. 2011;8:67.
- 720 50. Baan E, de Ronde A, Stax M, Sanders RW, Luchters S, Vyankandondera J, et al. HIV-1  
721 autologous antibody neutralization associates with mother to child transmission. *PLoS One*.  
722 2013;8(7):e69274.
- 723 51. Milligan C, Omenda MM, Chohan V, Odem-Davis K, Richardson BA, Nduati R, et al.  
724 Maternal Neutralization-Resistant Virus Variants Do Not Predict Infant HIV Infection Risk.  
725 *mBio*. 2016;7(1):e02221-15.
- 726 52. Fouda GG, Mahlokozera T, Salazar-Gonzalez JF, Salazar MG, Learn G, Kumar SB, et al.  
727 Postnatally-transmitted HIV-1 Envelope variants have similar neutralization-sensitivity and  
728 function to that of nontransmitted breast milk variants. *Retrovirology*. 2013;10:3.
- 729 53. Thenin S, Samleerat T, Tavernier E, Ngo-Giang-Huong N, Jourdain G, Lallemand M, et al.  
730 Envelope glycoproteins of human immunodeficiency virus type 1 variants issued from mother-  
731 infant pairs display a wide spectrum of biological properties. *Virology*. 2012;426(1):12-21.
- 732 54. van Gils MJ, Bunnik EM, Boeser-Nunnink BD, Burger JA, Terlouw-Klein M, Verwer N, et  
733 al. Longer V1V2 region with increased number of potential N-linked glycosylation sites in the

- 734 HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies. *J Virol.*  
735 2011;85(14):6986-95.
- 736 55. Rong R, Li B, Lynch RM, Haaland RE, Murphy MK, Mulenga J, et al. Escape from  
737 autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple  
738 pathways. *PLoS Pathog.* 2009;5(9):e1000594.
- 739 56. Gray ES, Moore PL, Choge IA, Decker JM, Bibollet-Ruche F, Li H, et al. Neutralizing  
740 antibody responses in acute human immunodeficiency virus type 1 subtype C infection. *J Virol.*  
741 2007;81(12):6187-96.
- 742 57. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, et al. Passive neutralizing  
743 antibody controls SHIV viremia and enhances B cell responses in infant macaques. *Nat Med.*  
744 2010;16(10):1117-9.
- 745 58. Himes JE, Goswami R, Mangan RJ, Kumar A, Jeffries TL, Jr., Eudailey JA, et al. Polyclonal  
746 HIV envelope-specific breast milk antibodies limit founder SHIV acquisition and cell-associated  
747 virus loads in infant rhesus monkeys. *Mucosal Immunol.* 2018;11(6):1716-26.
- 748 59. Stiehm ER, Lambert JS, Mofenson LM, Bethel J, Whitehouse J, Nugent R, et al. Efficacy of  
749 zidovudine and human immunodeficiency virus (HIV) hyperimmune immunoglobulin for  
750 reducing perinatal HIV transmission from HIV-infected women with advanced disease: results  
751 of Pediatric AIDS Clinical Trials Group protocol 185. *J Infect Dis.* 1999;179(3):567-75.
- 752 60. Onyango-Makumbi C, Omer SB, Mubiru M, Moulton LH, Nakabiito C, Musoke P, et al.  
753 Safety and efficacy of HIV hyperimmune globulin for prevention of mother-to-child HIV  
754 transmission in HIV-1-infected pregnant women and their infants in Kampala, Uganda  
755 (HIVIGLOB/NVP STUDY). *J Acquir Immune Defic Syndr.* 2011;58(4):399-407.
- 756 61. Caskey M, Schoofs T, Gruell H, Settler A, Karagounis T, Kreider EF, et al. Antibody 10-  
757 1074 suppresses viremia in HIV-1-infected individuals. *Nat Med.* 2017;23(2):185-91.

- 758 62. Ledgerwood JE, Coates EE, Yamshchikov G, Saunders JG, Holman L, Enama ME, et al.  
759 Safety, pharmacokinetics and neutralization of the broadly neutralizing HIV-1 human  
760 monoclonal antibody VRC01 in healthy adults. *Clin Exp Immunol.* 2015;182(3):289-301.
- 761 63. Lynch RM, Boritz E, Coates EE, DeZure A, Madden P, Costner P, et al. Virologic effects of  
762 broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. *Sci Transl*  
763 *Med.* 2015;7(319):319ra206.
- 764 64. Caskey M, Klein F, Lorenzi JC, Seaman MS, West AP, Jr., Buckley N, et al. Viraemia  
765 suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. *Nature.*  
766 2015;522(7557):487-91.
- 767 65. Cunningham CK, McFarland EJ, Morrison RL, Capparelli EV, Safrit JT, Mofenson LM, et  
768 al. Safety, Tolerability, and Pharmacokinetics of the Broadly Neutralizing Human  
769 Immunodeficiency Virus (HIV)-1 Monoclonal Antibody VRC01 in HIV-Exposed Newborn  
770 Infants. *J Infect Dis.* 2020;222(4):628-36.
- 771 66. Gruell H, Klein F. Antibody-mediated prevention and treatment of HIV-1 infection.  
772 *Retrovirology.* 2018;15(1):73.
- 773 67. Mahomed S, Garrett N, Baxter C, Abdool Karim Q, Abdool Karim SS. Clinical trials of  
774 broadly neutralizing monoclonal antibodies for HIV prevention: a review. *The Journal of*  
775 *Infectious Diseases.*
- 776 68. Heckman JJ. Sample Selection Bias as a Specification Error. *Econometrica.* 1979;47(1):153-  
777 61.
- 778 69. Gouy M, Guindon S, Gascuel O. SeaView version 4: A multiplatform graphical user  
779 interface for sequence alignment and phylogenetic tree building. *Mol Biol Evol.* 2010;27(2):221-  
780 4.

- 781 70. Kirchherr JL, Lu X, Kasongo W, Chalwe V, Mwananyanda L, Musonda RM, et al. High  
782 throughput functional analysis of HIV-1 env genes without cloning. *J Virol Methods*.  
783 2007;143(1):104-11.
- 784 71. Montefiori DC. Measuring HIV neutralization in a luciferase reporter gene assay. *Methods*  
785 *Mol Biol*. 2009;485:395-405.
- 786 72. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, et al. Human  
787 immunodeficiency virus type 1 env clones from acute and early subtype B infections for  
788 standardized assessments of vaccine-elicited neutralizing antibodies. *J Virol*.  
789 2005;79(16):10108-25.
- 790 73. Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG, et al.  
791 Identification and characterization of transmitted and early founder virus envelopes in primary  
792 HIV-1 infection. *Proc Natl Acad Sci U S A*. 2008;105(21):7552-7.
- 793 74. Dessau RB, Phipps CB. ["R"--project for statistical computing]. *Ugeskr Laeger*.  
794 2008;170(5):328-30.
- 795 75. Douglas Bates MM, Ben Bolker, Steve Walker Fitting Linear Mixed-Effects Models Using  
796 lme4. *Journal of Statistical Software*. 2015;67(1):1-48.
- 797 76. Gnanakaran S, Daniels MG, Bhattacharya T, Lapedes AS, Sethi A, Li M, et al. Genetic  
798 signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing  
799 antibodies. *PLoS Comput Biol*. 2010;6(10):e1000955.
- 800 77. Bhattacharya T, Daniels M, Heckerman D, Foley B, Frahm N, Kadie C, et al. Founder  
801 effects in the assessment of HIV polymorphisms and HLA allele associations. *Science*.  
802 2007;315(5818):1583-6.
- 803 78. Storey JD, Tibshirani R. Statistical significance for genomewide studies. *Proc Natl Acad Sci*  
804 *U S A*. 2003;100(16):9440-5.

805 79. deCamp A, Hraber P, Bailer RT, Seaman MS, Ochsenbauer C, Kappes J, et al. Global panel  
806 of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing  
807 antibodies. *J Virol*. 2014;88(5):2489-507.

808 80. Hraber P, Korber B, Wagh K, Montefiori D, Roederer M. A single, continuous metric to  
809 define tiered serum neutralization potency against HIV. *Elife*. 2018;7.

810 81. Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C, Giri A, et al. Tiered  
811 categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing  
812 antibodies. *J Virol*. 2010;84(3):1439-52.

813

814 **Supporting information**

815 **S1 Table.** Clinical characteristics and number of single genome amplified (SGA) plasma HIV

816 env sequences isolated for non-transmitting mothers.

817 **S2 Table.** Clinical characteristics for transmitting mothers and their infants.

818 **S3 Table.** Signature Sequence analysis of the envelope gene and association of amino acid sites

819 with transmission.

## 820 **Figure legends**

821 **Fig.1 Phylogenetic tree analysis of *env* SGA from non-transmitting mothers.** Neighbor  
822 joining phylogenetic tree were prepared using the Kimura 2 parameter method. Each colored  
823 dot represents an *env* amplicon, while red dots represent the amplicons selected for Env  
824 pseudovirus preparation.

## 825 **Figure 2: Phylogenetic tree analysis of *env* SGA from transmitting mother-infant pairs.**

826 Neighbor joining phylogenetic tree was prepared using the Kimura 2 parameter method. Each  
827 infant and mother *env* amplicons were shown as black and blue dots. Red dots represent the  
828 maternal amplicons selected for pseudovirus preparation while infant T/F viruses are shown by  
829 red arrow.

## 830 **Figure 3: Similar neutralization sensitivity of non-transmitted maternal variants from**

831 **transmitting and non-transmitting mothers to paired maternal plasma, while infant T/F**

832 **variants are more resistant to paired plasma than all maternal variants.** Maternal plasma

833 potency (ID<sub>50</sub>) against viruses from non-transmitting mothers (A) and transmitting mothers (B)

834 and infant T/Fs (C, red) and their paired closest maternal sequences (C, magenta). Boxes denote

835 interquartile distributions. Bottom panels: geometric mean ID<sub>50</sub> of non-transmitted variants

836 from each non-transmitting mothers (light blue) and transmitting mothers (dark blue) compared

837 to geometric mean of autologous ID<sub>50</sub> of infant T/Fs (red) and closest maternal sequences

838 (magenta). P-values were obtained from fitting a random-effect GLM model. Panel D shows the

839 comparison between all non-transmitted variants and infant T/Fs considered together with the

840 closest maternal sequences. Panel E shows the comparison all non-transmitted variants and the

841 infant T/Fs alone. Panel F shows the comparison between the non-transmitted variants from the

842 transmitting mothers and their paired infant T/Fs.

## 843 **Figure 4: Neutralization sensitivity of infant and maternal Env variants against a panel of**

844 **bnAbs.** Heatmap of bnAbs VRC01, PG9, DH512 and DH429 IC<sub>50</sub> against non-transmitting,

845 transmitting, and infant T/F variants, generated using the Heatmap tool on the Los Alamos HIV  
846 Database. Rows represent viruses and columns represent bnAbs. The darker hues indicate more  
847 potent neutralization, and aquamarine indicates IC50s above threshold, unable to reach this  
848 level of neutralization at the highest concentration of bnAb tested. Top rows (indicated by the  
849 light blue column to the left) are the variants from the non-transmitting mothers, below (dark  
850 blue on the left) are the non-transmitted variants from transmitting mothers, followed by infant  
851 T/Fs (red) and transmitting mother variants closest to the infant T/Fs (magenta, bottom).

852

853 **Figure 5: Logo plots of identified signature sequence sites of maternal HIV-1 Env variants**  
854 **that associate with bnAb sensitivity and/or maternal transmission status.** Logo plots are  
855 shown for each residue that was found to be associated with one of the tested features (see  
856 Material and Methods) at the FDR  $q < 0.05$  significance level, grouped by transmitting mothers  
857 (top) and non-transmitting mothers (bottom). Each amino acid logo is proportional in size to its  
858 relative frequency in the alignment. The letter “O” is used to designate N-linked glycosylation  
859 sites. Logos colored in red represent mutated amino acids that conferred resistance to one of the  
860 bnAbs tested (shown at the bottom), while logos in light blue represent mutations that conferred  
861 sensitivity. Orange denotes amino acids associated with transmission status. Notice that while  
862 the logo plots represent the frequency of each amino acid, this doesn’t always reflect the counts  
863 of ancestral mutations, which is what is tested in the phylogenetically-corrected signature  
864 analysis.

865 **Figure 6: Neutralization sensitivity of global panel of heterologous tier 2 viruses to plasma**  
866 **from transmitting and non-transmitting mothers.** Rows represent viruses and columns  
867 represent plasma from the transmitting and non-transmitting mothers. The darker hues indicate  
868 more potent neutralization, and aquamarine indicates ID<sub>50</sub>s below threshold, unable to reach this  
869 level of neutralization at the lowest dilution. Top rows (indicated by the dark blue column to the

870 left) are the plasma from the transmitting mothers, below (light blue on the left) are plasmas  
871 from transmitting mothers.




Fig. 1




Fig. 2




Fig. 3




Fig. 4




Fig. 5




Fig. 6